Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Cedar Grove Capital Management Paul Cerro | “Hims & Hers Health ($HIMS) provides direct-to-consumer digital telehealth services, offering subscription consultations and personalized treatments across dermatology, sexual health, mental wellness, and weight loss. The manager is bullish on the stock, projecting that continued execution could triple the fund's investment over the coming years. Economically, Hims operates an asset-light recurring subscription platform outside traditional third-party insurance reimbursement. Operating entirely in the cash-pay arena provides pricing transparency, eliminates complex claims administration, and generates high customer lifetime value relative to customer acquisition costs, leading to powerful incremental operating margins as scale grows. Key catalysts include product assortment expansion, growing adoption of customized multi-ingredient formulations, and international penetration. Downside risks include competitive pressure from incumbent pharmaceutical retailers, customer churn, and regulatory scrutiny regarding compounding medications.” | BULL | Q3 2026 Oct 5, 2026 | View Pitch |
Cedar Grove Capital Management Paul Cerro | “Our biggest contributors of the quarter were The Oncology Institute (TOI), Hims and Hers Health (HIMS), and uniQure NV (QURE). Some of you may or may not know, but we have a long history with HIMS, technically going back all the way to 2021. More recently, we were one of the first bears that initially pointed out its overall reliance on compounded GLP-1 medications, to its shady prescribing practices for the same drug that led to Novo Nordisk (NVO) terminating their first partnership with the company, and finally, the eventual patent infringement suit against the company by Novo Nordisk in February. Despite us being bears, we did hold a long position in the company for all of 2024 with the belief in the future of telehealth. Now that the messiness of compounded GLP-1 drugs is behind the company (hopefully), we ended up taking a position in the company the day after they reported Q1 earnings. We will share more in the coming weeks about our thesis, but for now, it represents our second biggest holding of the fund.” | BULL | Q2 2026 Jul 15, 2026 | View Pitch |
Heptagon Kettle Hill US L/S Equity Fund Andrew Y. Kurita, CFA | “The manager shorted the stock due to concerns over decelerating subscriber growth and the risk of cheaper oral GLP-1 alternatives impacting earnings estimates. They successfully covered a portion of the short position for a profit as the stock declined in anticipation of these issues.” | BEAR | Q4 2025 Dec 31, 2025 | View Pitch |
ACATIS Investment Dr. Hendrik Leber | “Hims & Hers is an American telemedicine start-up that facilitates discreet online access to gender-specific and (frequently also) prescription-only medication for sensitive health problems such as impotence, skin rashes and excess weight. These are health problems where customers value discretion, and they often lead to recurring sales through the provision of a regular supply. With a takeover, the company now wants to expand internationally and should benefit from rising user numbers and higher profitability in the long term. BSD Analysis: Hims & Hers reported an impressive 28.4% revenue surge in late 2025, reaching $617.8 million and topping GAAP earnings estimates with $0.08 per share. However, the 2026 outlook has set a cautious tone, with management forecasting first-quarter revenue slightly below consensus, leading to a temporary plunge in the share price. Despite this "soft" outlook, the company expects full-year 2026 sales to reach between $2.7 billion and $2.9 billion, a range that exceeds initial analyst expectations. Investors remain hyper-focused on the growth of the weight-loss segment and the impact of regulatory scrutiny on compounded GLP-1 products. The planned acquisition of Eucalyptus in mid-2026 is expected to act as a significant growth catalyst that is not yet fully reflected in current projections.” | BULL | Q3 2025 Oct 6, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.